Ascentage Pharma Group International (6855) Stock Overview
A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
6855 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ascentage Pharma Group International Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$31.18 |
| 52 Week High | HK$95.35 |
| 52 Week Low | HK$30.44 |
| Beta | 0.65 |
| 1 Month Change | -20.94% |
| 3 Month Change | -32.16% |
| 1 Year Change | -60.71% |
| 3 Year Change | 52.47% |
| 5 Year Change | -33.66% |
| Change since IPO | -17.07% |
Recent News & Updates
Narrative Update • Jun 18
6855: Late Stage Hematology Readouts And Trials Will Drive Future Upside Potential
Analysts have modestly adjusted their fair value estimate for Ascentage Pharma Group International stock to HK$72.45, citing updated views on revenue growth, profit margins and long term P/E assumptions following recent coverage that highlights its approved drugs in China and multiple ongoing global trials. Analyst Commentary Street research on Ascentage Pharma Group International highlights both enthusiasm for its approved drugs in China and ongoing global trials, and a more cautious thread that centers on execution risk and how much of that potential is already reflected in the current valuation.
Narrative Update • Jun 03
6855: Late Stage Hematology Data Readouts Will Support A More Constructive Outlook
Analysts have trimmed their fair value estimate for Ascentage Pharma Group International slightly, to about HK$114 from around HK$114 previously, as they factor in updated assumptions on discount rate, revenue growth, profit margin and future P/E, while highlighting growing interest in the company's late stage pipeline assets such as Olverembatinib and Lisaftoclax. Analyst Commentary Recent commentary from bullish analysts has centered on the potential of Ascentage Pharma Group International's late stage pipeline, particularly Olverembatinib and Lisaftoclax, as key drivers that could support the stock's valuation over the medium term.Recent updates
Narrative Update • Jun 18
6855: Late Stage Hematology Readouts And Trials Will Drive Future Upside Potential
Analysts have modestly adjusted their fair value estimate for Ascentage Pharma Group International stock to HK$72.45, citing updated views on revenue growth, profit margins and long term P/E assumptions following recent coverage that highlights its approved drugs in China and multiple ongoing global trials. Analyst Commentary Street research on Ascentage Pharma Group International highlights both enthusiasm for its approved drugs in China and ongoing global trials, and a more cautious thread that centers on execution risk and how much of that potential is already reflected in the current valuation.Narrative Update • Jun 03
6855: Late Stage Hematology Data Readouts Will Support A More Constructive Outlook
Analysts have trimmed their fair value estimate for Ascentage Pharma Group International slightly, to about HK$114 from around HK$114 previously, as they factor in updated assumptions on discount rate, revenue growth, profit margin and future P/E, while highlighting growing interest in the company's late stage pipeline assets such as Olverembatinib and Lisaftoclax. Analyst Commentary Recent commentary from bullish analysts has centered on the potential of Ascentage Pharma Group International's late stage pipeline, particularly Olverembatinib and Lisaftoclax, as key drivers that could support the stock's valuation over the medium term.Narrative Update • May 10
6855: Late Stage Oncology Readouts Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for Ascentage Pharma Group International to about HK$71.81 from roughly HK$91.17, citing updated assumptions for revenue growth, profit margins and future P/E expectations, even as recent research highlights potential from key late stage pipeline assets Olverembatinib and Lisaftoclax. Analyst Commentary Recent Street research highlights a split in sentiment around Ascentage Pharma Group International.Narrative Update • Apr 23
6855: Late Stage Hematology Readouts Will Drive A More Constructive Outlook
Analysts have adjusted their price target on Ascentage Pharma Group International to HK$114.00 from HK$117.46, citing refined assumptions for fair value, discount rate, revenue growth, profit margin and future P/E in light of recent Street research that highlights the potential of Olverembatinib and Lisaftoclax as key pipeline drivers. Analyst Commentary Bullish analysts point to the refined HK$114.00 price target as a reflection of updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E, all anchored in the progress of Olverembatinib and Lisaftoclax.Narrative Update • Apr 08
6855: Late Stage Hematology Pipeline Progress Will Support A More Constructive Outlook
Narrative Update The analyst price target for Ascentage Pharma Group International has been adjusted to HK$48. Analysts cite updated fair value estimates, revised assumptions for revenue growth and profit margins, and higher conviction in key late stage assets such as Olverembatinib and Lisaftoclax as the main drivers of this change.Analysis Article • Mar 29
Analysts Have Lowered Expectations For Ascentage Pharma Group International (HKG:6855) After Its Latest Results
Investors in Ascentage Pharma Group International ( HKG:6855 ) had a good week, as its shares rose 7.7% to close at...
Narrative Update • Mar 25
6855: Late Stage Oncology Pipeline Will Drive Bullish Repricing Potential
Analysts have lifted their price target on Ascentage Pharma Group International to HK$101.03 from HK$92.81, citing stronger confidence in the value of its late stage pipeline. This includes multiple Phase 3 programs for Olverembatinib and Lisaftoclax highlighted in recent research initiations.Narrative Update • Mar 11
6855: New BTK Degrader Progress Will Support A More Constructive Outlook
Narrative Update on Ascentage Pharma Group International Analysts have lifted their HK$ price target on Ascentage Pharma Group International to reflect a fair value estimate of about HK$116.73, supported by updated assumptions on revenue growth, profit margins, discount rate and a revised future P/E multiple following new bullish Street coverage. Analyst Commentary Bullish analysts have initiated coverage of Ascentage Pharma Group International with optimistic views on the company’s long term potential, backing their stance with explicit upside targets and a constructive read on the business model and execution risks.Narrative Update • Feb 25
6855: Future Clinical Milestones And New IND Clearances Will Drive Upside
Analysts have lifted their 12 month price target for Ascentage Pharma Group International to HK$91.17 from HK$60.10, citing updated assumptions for revenue growth, profit margins, discount rate and a higher future P/E multiple supported by recent bullish coverage and a HK$48 initiating target from Rodman & Renshaw. Analyst Commentary Recent research coverage on Ascentage Pharma Group International has been framed around detailed assumptions for revenue growth, profitability, discount rate and future P/E multiples.Narrative Update • Feb 10
6855: Future Clinical Data Readouts Will Support Long Term Upside Potential
Analysts have nudged their price target on Ascentage Pharma Group International slightly lower to $48, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations following fresh Street research coverage. Analyst Commentary Street research coverage on Ascentage Pharma Group International has crystallized around a $48 price target, with coverage framed positively but paired with a more measured stance on execution, valuation, and growth assumptions.Narrative Update • Jan 27
6855: Updated Drug Pipeline Progress Will Support A More Optimistic Outlook
Analysts have raised their fair value estimate for Ascentage Pharma Group International from US$92.99 to US$114.00. They cite recent bullish coverage and a new US$48 Street price target, which reflects updated views on growth, profitability, and future P/E assumptions.Narrative Update • Jan 12
6855: Future Clinical Data Will Support Balanced Long Term Risk Reward Profile
Analysts have trimmed their price target on Ascentage Pharma Group International, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, a small improvement in projected profit margins, and a higher future P/E multiple in their updated models. What's in the News The FDA cleared the IND for APG-3288, Ascentage Pharma Group International's BTK-targeted protein degrader, allowing a clinical study in patients with relapsed or refractory B-cell malignancies in the US (Key Developments).Narrative Update • Dec 27
6855: Future Clinical Data Will Support Stronger Long Term Risk Reward Profile
Analysts have slightly reduced their price target for Ascentage Pharma Group International to reflect a modest adjustment in assumed fair value and profit margins, partly offset by marginally higher expectations for long term revenue growth and a richer future price to earnings multiple. What's in the News Four year follow up data from a registrational Phase II trial showed Olverembatinib delivered significantly longer event free survival than best available therapy in TKI resistant or intolerant CML CP, with a favorable long term safety profile, reinforcing its differentiated efficacy.Narrative Update • Dec 13
6855: Future Data And Revenue Mix Will Support Balanced Risk Profile
Narrative Update on Ascentage Pharma Group International Analysts have raised their price target for Ascentage Pharma Group International from approximately $52 to about $60, citing sharply improved revenue growth expectations, a slightly stronger profit margin outlook, and a modestly lower future P/E multiple despite a higher discount rate. What's in the News Four year follow up data from a registrational Phase II trial showed Olverembatinib delivering markedly longer event free survival than best available therapy in TKI resistant or intolerant CML CP, while maintaining a favorable long term safety profile (ASH 2025 poster).Narrative Update • Sep 06
Takeda Deal And Olverembatinib Trials Will Open Global Markets
The consensus price target for Ascentage Pharma Group International has been raised, primarily reflecting improved future revenue growth forecasts, with fair value increasing from HK$84.05 to HK$92.81. What's in the News Lisaftoclax (APG-2575), Ascentage Pharma’s Bcl-2 inhibitor, received FDA and EMA clearance for the global Phase III GLORA-4 trial in combination with azacitidine for newly diagnosed higher-risk MDS, with strong ORR results and potential to reshape the treatment landscape as the first global Bcl-2 inhibitor for first-line HR-MDS.Narrative Update • Aug 22
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Driven by sharply improved net profit margin (from 3.01% to 37.85%) and much higher consensus revenue growth forecasts (from 19.7% to 72.0% per annum), the fair value estimate for Ascentage Pharma Group International has been raised to HK$84.05 from HK$75.50. What's in the News Lisaftoclax (APG-2575), Ascentage Pharma's proprietary Bcl-2 inhibitor, received clearance from the US FDA, EMA, and China CDE for the global Phase III GLORA-4 study in higher-risk myelodysplastic syndrome (HR-MDS); if successful, it could become the first approved Bcl-2 inhibitor for first-line HR-MDS.Analysis Article • Jun 10
Ascentage Pharma Group International's (HKG:6855) 25% Price Boost Is Out Of Tune With Revenues
Ascentage Pharma Group International ( HKG:6855 ) shares have continued their recent momentum with a 25% gain in the...Analysis Article • May 12
Here's Why Shareholders Will Not Be Complaining About Ascentage Pharma Group International's (HKG:6855) CEO Pay Packet
Key Insights Ascentage Pharma Group International will host its Annual General Meeting on 19th of May Total pay for CEO...Analysis Article • Apr 24
Ascentage Pharma Group International's (HKG:6855) 38% Price Boost Is Out Of Tune With Revenues
Ascentage Pharma Group International ( HKG:6855 ) shareholders have had their patience rewarded with a 38% share price...
New Narrative • Mar 30
Takeda Deal And Olverembatinib Trials Will Open Global Markets
Ascentage's strategic alliances and NRDL inclusion are set to enhance market reach, boost accessibility, and drive substantial revenue growth.Analysis Article • Dec 23
What Ascentage Pharma Group International's (HKG:6855) P/S Is Not Telling You
You may think that with a price-to-sales (or "P/S") ratio of 13.8x Ascentage Pharma Group International ( HKG:6855 ) is...Analysis Article • Sep 04
Ascentage Pharma Group International's (HKG:6855) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, Ascentage Pharma Group International ( HKG:6855 ) shares have been powering on, with a...Analysis Article • Aug 26
Here's Why Ascentage Pharma Group International (HKG:6855) Can Afford Some Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 18
Ascentage Pharma Group International's (HKG:6855) Shares Climb 29% But Its Business Is Yet to Catch Up
Ascentage Pharma Group International ( HKG:6855 ) shares have had a really impressive month, gaining 29% after a shaky...Analysis Article • May 03
Here's Why Ascentage Pharma Group International's (HKG:6855) CEO May Not Expect A Pay Rise This Year
Key Insights Ascentage Pharma Group International's Annual General Meeting to take place on 10th of May Salary of...Analysis Article • Mar 30
Why We're Not Concerned Yet About Ascentage Pharma Group International's (HKG:6855) 30% Share Price Plunge
The Ascentage Pharma Group International ( HKG:6855 ) share price has fared very poorly over the last month, falling by...Shareholder Returns
| 6855 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.6% | 1.2% | -3.8% |
| 1Y | -60.7% | -12.0% | -2.3% |
Return vs Industry: 6855 underperformed the Hong Kong Biotechs industry which returned -12% over the past year.
Return vs Market: 6855 underperformed the Hong Kong Market which returned -2.3% over the past year.
Price Volatility
| 6855 volatility | |
|---|---|
| 6855 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 16.2% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 6855 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6855's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 767 | Dajun Yang | www.ascentage.cn |
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin’s lymphoma.
Ascentage Pharma Group International Fundamentals Summary
| 6855 fundamental statistics | |
|---|---|
| Market cap | HK$11.48b |
| Earnings (TTM) | -HK$1.43b |
| Revenue (TTM) | HK$662.14m |
17.3x
P/S Ratio-8.0x
P/E RatioIs 6855 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6855 income statement (TTM) | |
|---|---|
| Revenue | CN¥574.12m |
| Cost of Revenue | CN¥48.94m |
| Gross Profit | CN¥525.18m |
| Other Expenses | CN¥1.77b |
| Earnings | -CN¥1.24b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 91.48% |
| Net Profit Margin | -216.47% |
| Debt/Equity Ratio | 146.7% |
How did 6855 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/25 16:48 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascentage Pharma Group International is covered by 25 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yang Huang | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Suranjit Mukherjee | BTIG |